The 2025 ONS/ASCO Guideline on the Management of Antineoplastic Extravasation addresses paclitaxel extravasation as a taxane-related event and provides a conditional recommendation, based on very low-certainty evidence, to use an antidote rather than no antidote for paclitaxel or docetaxel extravasation; the studies informing this recommendation used hyaluronidase. The guideline identifies hyaluronidase as the antidote used for extravasation of paclitaxel and docetaxel, with an example regimen of 150 units/1 mL divided into five 0.2-mL subcutaneous injections around the perimeter of the extravasation site using a 25-gauge needle, administered within 3 to 4 hours of extravasation. In addition, the guideline suggests use of a thermal compress rather than no compress and a longer duration of compress application, with warm compresses indicated for paclitaxel when coadministered with hyaluronidase, while the algorithm lists cold compresses for taxanes when hyaluronidase is not used. Initial management in the guideline algorithm includes stopping the infusion, assessing the site, notifying the care team according to local processes, attempting slow aspiration without flushing, removing the peripheral IV cannula or implanted port access while avoiding firm pressure, measuring and outlining the affected area, applying the appropriate thermal compress for 15–20 minutes three to four times daily for 48–72 hours, and continuing assessment and follow-up. [1]
The 2024 multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology on extravasation associated with cancer drug therapy does not identify a preferred treatment specifically for paclitaxel extravasation. Instead, paclitaxel is classified as a vesicant based on reports of extravasation-related necrosis, and management is guided by general vesicant extravasation principles. Recommended measures include prompt discontinuation of the infusion, clinical assessment, and local treatment with cold compression, which was weakly recommended to reduce pain, inflammation, and progression of tissue injury. Warm compression alone and local steroid injection were weakly discouraged, while topical steroid application was weakly recommended based on limited indirect evidence. The guideline did not make a recommendation regarding aspiration of residual drug or blood because evidence was insufficient. [2]
The 2012 ESMO-EONS Clinical Practice Guideline on the Management of Chemotherapy Extravasation classifies paclitaxel and docetaxel as vesicants and recommends hyaluronidase for taxane extravasation. Hyaluronidase is described as an enzyme that degrades hyaluronic acid and may enhance absorption of extravasated drug. The guideline cites animal data demonstrating reduced ulcer formation with hyaluronidase and a small study of seven patients with vinca alkaloid extravasation in whom no skin necrosis occurred following treatment. Based on the available evidence, the guideline recommends subcutaneous hyaluronidase (150–900 IU) administered around the area of extravasation for taxane extravasation. The guideline also emphasizes prompt recognition and management of extravasation and notes that evidence supporting many interventions is limited and derived primarily from non-randomized studies and case reports. [3]
A 2023 review article examined paclitaxel extravasation events drawn from various case reports and analyzed its vesicant potential. The primary objective of the review was to summarize existing reports on extravasations involving paclitaxel, an anti-neoplastic with broad anti-tumor activity, and evaluate its potential to cause local tissue necrosis. Early clinical studies did not report significant local tissue necrosis from paclitaxel; however, more recent case reports suggested otherwise. The authors explored management strategies for extravasation events, particularly in patients receiving intravenous chemotherapy. According to the review, the risk classification of chemotherapy agents, as either irritants or vesicants, is crucial as it informs the approach to managing extravasation injuries. Grading scales of injection site reactions were also evaluated, such as those from the National Cancer Institute and the Gynecologic Oncology Group, revealing a range of reactions from transient erythema to ulceration requiring surgical intervention. The review detailed numerous case reports of paclitaxel extravasation, highlighting incidents of erythema, edema, and varying degrees of tissue reaction including necrosis. In most cases, patients experienced tissue injury of varying severity despite different administered concentrations. The therapeutic responses varied, with management strategies ranging from the application of heat or cold compresses, and in some reports, the use of hyaluronidase as an antidote was explored. The findings indicated no direct correlation between the concentration or volume of extravasated paclitaxel and the severity of tissue damage. However, the review reinforced that both the drug and its Cremophor EL diluent have mild vesicant properties that could contribute to the ulcerative potential. Despite the potential for adverse local reactions, some case reports identified complete resolution without aggressive intervention, suggesting that paclitaxel might exhibit only mild vesicant properties. These findings point towards the necessity for rigorous preventive measures, like using central lines for drug administration, and highlight conservative strategies such as cold compresses that might mitigate injury severity. [4]
A 2014 review explores the controversial classification of taxanes—such as paclitaxel, docetaxel, and cabazitaxel—as either vesicants or irritants. The review highlights significant gaps in clinical guidance regarding the administration of these chemotherapeutic agents and their potential to cause tissue injury upon extravasation. The American Society of Clinical Oncology and Oncology Nursing Society Chemotherapy Administration Safety Standards, along with the Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, comprehensively address certain aspects of chemotherapy safety. They highlight the risks of extravasation and establish protocols for the infusion of known vesicants. These standards also specify suitable administration sites for these agents and suggest antidotes for particular extravasation scenarios. However, they do not provide detailed guidance for the administration of individual taxanes. Additionally, there is an absence of a standardized classification system categorizing antineoplastic agents as vesicants, irritants, or inert compounds, leaving a gap in the specific recommendation framework for these agents. The review discusses various reports and studies indicating instances of tissue damage, such as blistering, associated with taxane extravasation. For example, docetaxel and paclitaxel were reported to cause blistering in a minimal number of cases, while albumin-bound paclitaxel extravasation has been associated more frequently with tissue injury, with postmarketing data reporting an incidence rate of 1.6% for all injection-site reactions. Consequently, many healthcare practitioners opt for central venous administration of taxanes as a precautionary measure, although evidence supporting its efficacy in reducing extravasation risk remains inconclusive. The review underscores the necessity for more robust classification systems and clearer clinical guidelines to ensure safer taxane administration practices. [5]